Company
Headquarters: Shenzhen, China
Employees: 1,217
HK$275.2 Million
HKD as of Jan. 1, 2024
US$35.2 Million
| Company | Market Cap (USD) |
|---|---|
| Zoetis Inc. | $89.09 B |
| MERCK Kommanditgesellschaft auf Aktien | $67.64 B |
| Takeda Pharmaceutical Company Limited | $47.71 B |
| Haleon plc | $38.90 B |
| PPD, Inc. | $16.58 B |
| Company | Market Cap (USD) |
|---|---|
| Lilly | $586.39 B |
| UnitedHealth Group | $504.47 B |
| Novo Nordisk | $461.52 B |
| Johnson & Johnson | $387.50 B |
| Merck | $296.51 B |
Shenzhen Neptunus Interlong Bio-technique Company Limited, together with its subsidiaries, researches, develops, produces, and sells medicines in the People's Republic of China. It is also involved in the purchase, sale, and distribution of medicines and healthcare food products; and research and development of biological technology products and in vitro diagnostic reagents. In addition, the company manufactures herbal medicines, generic drugs, and transfusion products, as well as medical devices. It serves approximately 500 medical organizations. The company is based in Shenzhen, the People's Republic of China. Shenzhen Neptunus Interlong Bio-technique Company Limited is a subsidiary of Shenzhen Neptunus Bio-engineering Company Limited.
Top 1-year algo backtest: +313.24%
$10,000 in May 2023 would now be $41,324 by following this algorithm daily at market close.
Boost your stocks returns with Disfold AI... Now!
Try Disfold AI for FREE
Shenzhen Neptunus Interlong Bio-technique Company Ltd has the following listings and related stock indices.
Stock: HKEX: 8329 wb_incandescent